In this exploratory study, high PARP1 expression and presence of BCR::ABL1 p190+ translocation were used as predictors of PARPi sensitivity in cohorts of B-cell neoplastic cell lines, with the observed similar cytotoxic profiles of PARPi, AZD2461, and gold standard treatment, imatinib, against a BCR::ABL1 p190+ ALL cell model fomenting the idea of utilizing PARP as a potential therapeutic target in this neoplastic model. Here, ABL1 is linked to acute lymphoblastic leukemia.